Gerald Horan
Company: Bristol Myers Squibb
Job title: Senior Director
Seminars:
Deep Diving into Biomarker Results From a Phase 2 Study of the CC-90001 JNK Inhibitor in NASH with Advanced Fibrosis 1:20 pm
Exploring how biomarkers can inform on mechanisms of fibrosis Treatment of F3 NASH Subjects with the CC-90001 JNK inhibitor associated with dose-dependent reductions in multiple biomarkers of fibrosis, including ELF and PRO-C3 Dose-dependent reductions in imaging MRE score were consistent with serum fibrosis biomarker results Effects of CC-90001 appeared to be mostly anti-fibrotic with little…Read more
day: Conf Day 1 Track 1 PM